Merck and Moderna’s Personalized mRNA Vaccine Succeeds in First Phase 3 Melanoma Trial

Merck and Moderna’s personalized mRNA vaccine with Keytruda reduced melanoma recurrence in a 1,137-patient Phase 3 trial—the first late-stage win for an mRNA cancer vaccine.